NVO changes
Pick any two versions below to diff them.
- Price
- $38.80 → $37.91(−2.3%)
- Discount
- 7.6% → 9.7%(+2.1 pts)
- Recent events
- 2026-09-29: Novo agreed to license HRS-1596 from Hengrui Pharma. HRS-1596 is an early-stage, once-weekly oral GLP-1/GIP obesity pill. Novo pays $300 million upfront. The deal can reach $2.6 billion with milestones. It excludes mainland China, Hong Kong, Macao and Taiwan, and should close in Q4 2026. 2026-09-21: At its Capital Markets Day, Novo set 2030 ambitions for revenue growth in line with a group of large pharmaceutical peers (not above them), broadly stable operating margins, and serving more than 60 million patients globally. The stock fell about 7.7% that day. The same day, Novo reported Phase 3 data showing CagriSema beat Eli Lilly's tirzepatide on weight loss (12.4% vs 9.1%) in people with type 2 diabetes. 2026-08-04: Novo reported Q2 2026 results: adjusted sales of DKK 78,488 million, up 7% at constant exchange rates, and adjusted operating profit of DKK 33,389 million, up 11%. Management raised full-year 2026 guidance to 0% to -6% growth (from -4% to -12%) for both adjusted sales and operating profit, citing stronger Wegovy pill demand. 2025-12-22: The FDA approved the Wegovy pill (oral semaglutide, 25 mg), the first oral GLP-1 medicine approved for weight management. It launched in the US in January 2026. 2025-11-06: Novo agreed to a pricing deal with the Trump administration, cutting Ozempic and Wegovy prices for Medicare, Medicaid, and a new consumer website, TrumpRx.gov, with Medicare set to begin covering obesity drugs for some patients from mid-2026, plus a three-year tariff exemption. 2025-10-21: Amid a board dispute over the pace of change, Chairman Helge Lund agreed to step down. Novo Holdings, controlled by the Novo Nordisk Foundation, said former Novo Nordisk CEO Lars Rebien Sørensen would become the new chairman, with more than half the board set to turn over. 2025-10-09: Novo agreed to acquire Akero Therapeutics for up to $5.2 billion ($54 per share in cash plus a $6 per share contingent payment), adding efruxifermin, a Phase 3 drug for the liver disease MASH. The deal closed in December 2025. 2025-09-10: New CEO Mike Doustdar, a little over a month into the role, announced plans to cut about 9,000 jobs (11% of the workforce) to save roughly DKK 8 billion ($1.3 billion) a year by the end of 2026, and to exit cell-therapy research.